コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 schizophrenia but improved performance among healthy comparison subjects.
2 ia, their nonpsychotic healthy siblings, and healthy comparison subjects.
3 ifferences between nonpsychotic siblings and healthy comparison subjects.
4 ee in adolescents with bulimia nervosa as in healthy comparison subjects.
5 matter difference between ADHD patients and healthy comparison subjects.
6 ere detected in bipolar patients relative to healthy comparison subjects.
7 s with nonpsychotic major depression, and 19 healthy comparison subjects.
8 Patients performed the task more slowly than healthy comparison subjects.
9 hrenia or recurrent depression as well as in healthy comparison subjects.
10 ren and adults with Tourette syndrome and in healthy comparison subjects.
11 in cocaine-dependent individuals relative to healthy comparison subjects.
12 in cocaine-dependent volunteers relative to healthy comparison subjects.
13 clinics and the community and matched to 31 healthy comparison subjects.
14 was not statistically different from that of healthy comparison subjects.
15 lative to patients with noncomorbid ADHD and healthy comparison subjects.
16 nia patients, 29 unaffected siblings, and 20 healthy comparison subjects.
17 ected first-degree relatives, and 30 matched healthy comparison subjects.
18 tter and larger third ventricle volumes than healthy comparison subjects.
19 een depressed patients without psychosis and healthy comparison subjects.
20 nia/schizoaffective disorder patients and 66 healthy comparison subjects.
21 er and larger lateral ventricle volumes than healthy comparison subjects.
22 an individual with schizophrenia, and 2) 236 healthy comparison subjects.
23 to depressed patients without psychosis and healthy comparison subjects.
24 l defiant disorder, 12 had ADHD, and 12 were healthy comparison subjects.
25 atients with depression subtypes relative to healthy comparison subjects.
26 tients with noncomorbid conduct disorder and healthy comparison subjects.
27 e-half of a standard deviation below that of healthy comparison subjects.
28 enia patients and 40 age- and gender-matched healthy comparison subjects.
29 ore prominent attention deficits relative to healthy comparison subjects.
30 h major depression without psychosis, and 3) healthy comparison subjects.
31 r panic disorder and 19 sex- and age-matched healthy comparison subjects.
32 a or schizoaffective disorder and 62 matched healthy comparison subjects.
33 nd/or antisocial personality disorder and in healthy comparison subjects.
34 e outcomes and were compared with 36 matched healthy comparison subjects.
35 luded 66 Tourette's syndrome patients and 70 healthy comparison subjects.
36 ssion and prepulse inhibition in relation to healthy comparison subjects.
37 y comparison subjects, and noncombat-exposed healthy comparison subjects.
38 tients with Tourette's syndrome with that of healthy comparison subjects.
39 ir unaffected first-degree relatives, and 54 healthy comparison subjects.
40 alamus in individuals with schizophrenia and healthy comparison subjects.
41 deficit hyperactivity disorder (ADHD) and 32 healthy comparison subjects.
42 hreshold and clinical depression relative to healthy comparison subjects.
43 d ADHD plus bipolar disorder, and seven were healthy comparison subjects.
44 th first-episode affective psychosis, and 23 healthy comparison subjects.
45 in the schizophrenia patients but not in the healthy comparison subjects.
46 with either major depression or PTSD and in healthy comparison subjects.
47 tudied 15 patients with schizophrenia and 26 healthy comparison subjects.
48 their activity in ADHD children relative to healthy comparison subjects.
49 phrenia) on measures of N-acetylaspartate in healthy comparison subjects.
50 D, 17 patients with trichotillomania, and 20 healthy comparison subjects.
51 major depressive disorder (MDD) relative to healthy comparison subjects.
52 ment task in patients with schizophrenia and healthy comparison subjects.
53 first-episode nonschizophrenia psychoses and healthy comparison subjects.
54 from 132 patients with schizophrenia and 177 healthy comparison subjects.
55 edication patients with schizophrenia and 22 healthy comparison subjects.
56 schizophrenia and 16 age- and gender-matched healthy comparison subjects.
57 asone would be unchanged in PTSD relative to healthy comparison subjects.
58 n 20 first-episode psychosis patients and 18 healthy comparison subjects.
59 ested in 10 panic disorder patients and nine healthy comparison subjects.
60 depression, patients with schizophrenia, and healthy comparison subjects.
61 ubjects with subsyndromal depression, and 21 healthy comparison subjects.
62 ion in 14 patients with schizophrenia and 15 healthy comparison subjects.
63 al basal ganglia significantly less than the healthy comparison subjects.
64 tes in patients with major depression and in healthy comparison subjects.
65 zophrenia or schizoaffective disorder and 22 healthy comparison subjects.
66 sion making differ in subjects with ADHD and healthy comparison subjects.
67 h chronic schizophrenia and 28 group-matched healthy comparison subjects.
68 with schizophrenia relative to their matched healthy comparison subjects.
69 , and 140 scans were acquired for 64 matched healthy comparison subjects.
70 izophrenia and in 34 (21 male and 13 female) healthy comparison subjects.
71 ce without comorbid axis I disorders, and 51 healthy comparison subjects.
72 a first episode of schizophrenia relative to healthy comparison subjects.
73 schizophrenia and in 14 male and nine female healthy comparison subjects.
74 hizophrenia patients with good outcomes, and healthy comparison subjects.
75 to examine this relationship in patients and healthy comparison subjects.
76 determined in autistic children and matched healthy comparison subjects.
77 rational families with schizophrenia and 249 healthy comparison subjects.
78 with childhood-onset schizophrenia than for healthy comparison subjects.
79 f plasma glucose, insulin, and cortisol than healthy comparison subjects.
80 ean age=33.6 years) and age- and sex-matched healthy comparison subjects.
81 sol measures did not differ between PTSD and healthy comparison subjects.
82 of schizophrenia and 30 age- and sex-matched healthy comparison subjects.
83 covered depressed patients and in 31 matched healthy comparison subjects.
84 ression, 25 with unipolar depression, and 37 healthy comparison subjects.
85 e affective psychosis (mainly manic), and 14 healthy comparison subjects.
86 medication free for at least 6 weeks and 41 healthy comparison subjects.
87 6 patients with chronic schizophrenia and 16 healthy comparison subjects.
88 c bipolar disorder was compared with that of healthy comparison subjects.
89 had smaller hippocampal volumes than did the healthy comparison subjects.
90 t in temporal lobe epilepsy patients than in healthy comparison subjects.
91 ts with first-episode affective psychosis or healthy comparison subjects.
92 patients with major depressive disorder and healthy comparison subjects.
93 tients with major depressive disorder and 42 healthy comparison subjects.
94 higher in the depressed patients than in the healthy comparison subjects.
95 iability for both schizophrenia patients and healthy comparison subjects.
96 patients with schizophrenia and 0.77 for the healthy comparison subjects.
97 iencing their first psychotic episode and 16 healthy comparison subjects.
98 ional connectivity in 44 OCD patients and 43 healthy comparison subjects.
99 and correct-related negativity compared with healthy comparison subjects.
100 zophrenia or schizoaffective disorder and 31 healthy comparison subjects.
101 rsons with alcohol dependence and 21 matched healthy comparison subjects.
102 uate-duration medication treatments), and 16 healthy comparison subjects.
103 f bipolar patients, unaffected siblings, and healthy comparison subjects.
104 None of these associations were observed in healthy comparison subjects.
105 disorder, their first-degree relatives, and healthy comparison subjects.
106 der compared with schizophrenia patients and healthy comparison subjects.
107 in 346 patients with schizophrenia and 2,342 healthy comparison subjects.
108 rformance in patients with schizophrenia and healthy comparison subjects.
109 tidepressant-naive depressed adolescents and healthy comparison subjects.
110 ateral prefrontal cortex (BA 46) relative to healthy comparison subjects.
111 uate-duration medication treatments), and 16 healthy comparison subjects.
112 inent cocaine-dependent subjects and matched healthy comparison subjects.
113 mild or moderate Alzheimer's disease, and 70 healthy comparison subjects.
114 egions, as compared with the repeat scans of healthy comparison subjects.
115 dren and adults with bipolar disorder and in healthy comparison subjects.
116 sing 450 patients with schizophrenia and 422 healthy comparison subjects.
117 ave been observed to have larger brains than healthy comparison subjects.
118 eater stop-signal reaction times relative to healthy comparison subjects.
119 dala, extending into the insula, relative to healthy comparison subjects.
121 phobia (25 adults and 14 adolescents) and 39 healthy comparison subjects (23 adults and 16 adolescent
122 91 with ADHD, 78 with subthreshold ADHD, 332 healthy comparison subjects; 55.8% male; average age: 17
127 ls with schizophrenia was slower than in any healthy comparison subject and correlated with both posi
131 nding in the striatum was 11.1% (SD=4.4%) in healthy comparison subjects and 5.7% (SD=5.9%) in cocain
132 ferences between the four patient groups and healthy comparison subjects and among the patient groups
133 ampal activity in schizophrenia patients and healthy comparison subjects and analyzed the relationshi
134 enia patients and 39 age- and gender-matched healthy comparison subjects and between 40 chronic schiz
135 gnificantly greater diffuse atrophy than the healthy comparison subjects and higher CSF volumes than
136 polar disorder and schizophrenia relative to healthy comparison subjects and identified putative expr
137 tal cortex area 9 of 57 schizophrenia and 57 healthy comparison subjects and in antipsychotic-exposed
138 responses specific to sad faces relative to healthy comparison subjects and nonmedicated patients in
139 in paranoid patient volunteers compared with healthy comparison subjects and nonparanoid patient volu
141 noverlapping regions of the thalamus in both healthy comparison subjects and schizophrenia patients.
142 subdivision (effect size=1.24) than did the healthy comparison subjects and showed a positive correl
144 es between large samples of OCD patients and healthy comparison subjects and their relation with demo
145 the largest effect size in comparisons with healthy comparison subjects and with affective psychosis
146 amygdala activation was reduced relative to healthy comparison subjects and youths with ADHD while p
147 ood in 690 individuals (479 patients and 211 healthy comparison subjects) and adjusted for a range of
148 chizophrenia did not propagate (as it did in healthy comparison subjects) and was mostly confined to
150 lates of habituation in borderline patients, healthy comparison subjects, and a psychopathological co
151 9 from 62 matched pairs of schizophrenia and healthy comparison subjects, and in situ hybridization t
152 ts were combat-PTSD patients, combat-exposed healthy comparison subjects, and noncombat-exposed healt
153 of these responses was impaired relative to healthy comparison subjects, and patients were more pron
154 ural synchrony in schizophrenia patients and healthy comparison subjects, and related prespeech neura
155 acquired from 17 children with autism and 14 healthy comparison subjects, and sulcal and gyral thickn
156 ior hippocampal formation volume relative to healthy comparison subjects but did not differ in volume
157 ssed patients and 46 age- and gender-matched healthy comparison subjects by using [(99m)Tc]TRODAT-1,
159 table outpatients with schizophrenia, and 36 healthy comparison subjects completed a range of social
160 (N=18) and high apathy levels (N=20) and 12 healthy comparison subjects completed neuropsychological
161 CS(pos) among those with the disorder, while healthy comparison subjects displayed no evidence of con
162 d from 52 patients with schizophrenia and 41 healthy comparison subjects during a standard auditory p
163 tric diagnoses with the abused group, and 27 healthy comparison subjects during an individually adjus
165 individuals with Tourette's syndrome and 21 healthy comparison subjects during spontaneous or simula
166 activity of 23 schizophrenia patients and 24 healthy comparison subjects during trials in which they
167 th Tourette's syndrome, OCD, or ADHD than in healthy comparison subjects; each diagnostic group seeme
170 EEG responses in schizophrenia patients and healthy comparison subjects following the application of
171 055 of their first-degree relatives, and 459 healthy comparison subjects for clinical characterizatio
172 cipate found between the Alzheimer's and the healthy comparison subjects for three of the four hypoth
173 tients with generalized social phobia and 16 healthy comparison subjects group-matched on age, gender
174 als with generalized anxiety disorder and 32 healthy comparison subjects group-matched on IQ, gender,
175 als with generalized anxiety disorder and 32 healthy comparison subjects group-matched on IQ, gender,
178 investigated whether depressed patients and healthy comparison subjects have differences in cortical
179 nic/mixed bipolar disorder (BP group) and 34 healthy comparison subjects (HC group) received an fMRI
180 hate (Pi) levels in 8 subjects with BD and 8 healthy comparison subjects (HCS) ages 11 to 20 years ol
181 between the recovered depressed patients and healthy comparison subjects in any of the brain regions
184 e exaggerated brain activation compared with healthy comparison subjects in multiple regions, includi
185 arge sample of schizophrenia outpatients and healthy comparison subjects in order to compare how thes
186 significantly lower glucose metabolism than healthy comparison subjects in parietal, temporal, occip
187 e consistently less accurate and slower than healthy comparison subjects in semantic decisions in whi
188 ative to neutral facial expressions than did healthy comparison subjects in the amygdala, orbitofront
189 er showed greater anticipatory activity than healthy comparison subjects in the bilateral dorsal amyg
190 to 10 unmedicated depressed patients and 12 healthy comparison subjects in the context of a 3T funct
191 exhibited significantly less activation than healthy comparison subjects in the left anterior insula.
192 sed subjects would show less activation than healthy comparison subjects, in response to positive sti
194 Thirty-six schizophrenia subjects and 28 healthy comparison subjects matched by age, gender, race
195 generalized anxiety disorder patients and 12 healthy comparison subjects matched for age, sex, and ed
196 y male chronic schizophrenia patients and 16 healthy comparison subjects matched with the patients fo
197 ents with first-episode schizophrenia and 24 healthy comparison subjects, matched on demographic char
198 age=41.6 years, 17 women and 17 men) and 33 healthy comparison subjects (mean age=41.3, 15 women and
206 ts (N=169) and age-, gender-, and IQ-matched healthy comparison subjects (N=173) were included in a q
208 onal magnetic resonance imaging (3 Tesla) in healthy comparison subjects (N=21) and in patients with
214 they scored within 0.5 standard deviation of healthy comparison subjects (N=30) on four tests of atte
216 ive Assessment of At-Risk Mental States, and healthy comparison subjects (N=38) 14 to 29 years of age
217 ts with major depressive disorder (N=12) and healthy comparison subjects (N=5) were scanned on three
218 full siblings (N=78, 172 scans), and matched healthy comparison subjects (N=79, 198 scans) between th
220 ividuals (combined-type ADHD patients: N=47; healthy comparison subjects: N=57), aged 7 to 18 years,
223 ments and performed significantly worse than healthy comparison subjects on most neuropsychological m
224 ral striatum to a greater extent relative to healthy comparison subjects on the parametric contrast o
225 ags (i.e., growth that is slower relative to healthy comparison subjects) on tests indexing processin
226 Ten adolescents with bipolar disorder and 10 healthy comparison subjects participated in a color-nami
228 and older outpatients with schizophrenia and healthy comparison subjects participating in research on
231 h anorexia nervosa, restricting type; and 13 healthy comparison subjects performed a rapid, jittered
232 Fourteen patients with schizophrenia and 14 healthy comparison subjects performed a smooth pursuit e
233 tients, 17 of their siblings, and 37 matched healthy comparison subjects performed a stop-signal task
234 nd, 21 outpatients with schizophrenia and 23 healthy comparison subjects performed a visual attention
235 teen medicated schizophrenia patients and 16 healthy comparison subjects performed an action imitatio
236 atients (ages 14-38 years) and eight matched healthy comparison subjects performing motor and attenti
237 y-two substance-dependent individuals and 30 healthy comparison subjects played a modified version of
240 behavior disorders and psychopathic traits, healthy comparison subjects showed a significantly great
241 esponse to conflict differently from that of healthy comparison subjects, specifically in frontal reg
242 cessful (relative to successful inhibition), healthy comparison subjects strongly activated the anter
243 cts with familial bipolar I disorder than in healthy comparison subjects, suggesting possible neurona
244 der and seven with major depression), and 10 healthy comparison subjects, the authors examined the ex
245 zophrenia or schizoaffective disorder and 25 healthy comparison subjects, the authors related prespee
248 etween patients with Tourette's syndrome and healthy comparison subjects, the two groups differed sig
249 al activity and interregional causality than healthy comparison subjects throughout all portions of t
250 depressed, and 24 were in remission) and 54 healthy comparison subjects underwent an indirect face-e
251 anxiety disorder and age- and gender-matched healthy comparison subjects underwent differential class
252 fully remitted from major depression, and 20 healthy comparison subjects underwent event-related func
253 ht schizophrenia patients and 28 age-matched healthy comparison subjects underwent functional "restin
254 chizophrenia/schizoaffective patients and 13 healthy comparison subjects underwent functional magneti
255 dicated depressed bipolar II patients and 21 healthy comparison subjects underwent functional MRI (fM
256 nts with generalized anxiety disorder and 24 healthy comparison subjects underwent functional MRI whi
257 ymic patients with bipolar I disorder and 31 healthy comparison subjects underwent MRI scanning.
258 er current psychiatric comorbidities, and 12 healthy comparison subjects underwent MRI with a 3-T sys
260 isode schizophrenia patients and 100 matched healthy comparison subjects underwent structural and res
261 DSM-IV criteria for major depression and 40 healthy comparison subjects underwent structural magneti
263 ing 18 outpatients with schizophrenia and 17 healthy comparison subjects, underwent scanning on a 3-T
264 ck working memory task is similar to that of healthy comparison subjects use greater prefrontal resou
265 ts with chronic schizophrenia and 12 matched healthy comparison subjects using [(11)C]IMA107 positron
266 stic children and 28 age- and gender-matched healthy comparison subjects was analyzed for numbers of
267 IV-defined depersonalization disorder and 22 healthy comparison subjects were administered the Dissoc
269 Ninety-one schizophrenia outpatients and 30 healthy comparison subjects were assessed on measures of
270 t-episode nonschizophrenia psychoses, and 77 healthy comparison subjects were assessed with the Perso
272 al high risk for psychosis and a group of 80 healthy comparison subjects were identified and recruite
273 tional anisotropy in patients in relation to healthy comparison subjects were identified by permutati
275 zophrenia or schizoaffective disorder and 34 healthy comparison subjects were included in the study.
276 DSM-IV-Text Revision diagnosis of GAD and 26 healthy comparison subjects were recruited and tested.
277 DSM-IV-TR diagnosis of panic disorder and 19 healthy comparison subjects were recruited for the study
281 cohol-dependent patients in treatment and 50 healthy comparison subjects were scanned once using high
282 ividuals who converted to psychosis, and 135 healthy comparison subjects were scanned with magnetic r
283 Ten subjects with specific phobia and 10 healthy comparison subjects were studied by using a seri
284 luding exposure and response prevention, and healthy comparison subjects were tested after a comparab
285 Fifty-nine schizophrenia patients and 17 healthy comparison subjects were tested on both P50 supp
286 social phobia and depressive disorder and 44 healthy comparison subjects were tested on dichotic fuse
287 rments among psychotic probands, compared to healthy comparison subjects, were progressively greater
288 trend-level lower fractional anisotropy than healthy comparison subjects, whereas the first-episode s
289 ) relative to both nonpsychotic siblings and healthy comparison subjects, whereas there were no signi
290 ng were recorded from 45 OCD patients and 39 healthy comparison subjects while performing a flanker t
291 vation in children with bipolar disorder and healthy comparison subjects while they performed a motor
292 who received sham EP-MRSI, and by four of 14 healthy comparison subjects who received actual EP-MRSI.
293 zophrenia or schizoaffective disorder and 30 healthy comparison subjects who received information abo
294 older adults and 52 age- and gender-matched healthy comparison subjects who underwent structural MRI
295 older adults and 52 age- and gender-matched healthy comparison subjects who underwent structural MRI
296 occurs in participants with PTSD relative to healthy comparison subjects who were either exposed or n
297 red in 33 patients with schizophrenia and 40 healthy comparison subjects with an automated voxel-base
298 d from 19 healthy first-degree relatives, 20 healthy comparison subjects with similar age and gender
299 ht adults with Asperger's syndrome and in 10 healthy comparison subjects with single photon emission
300 ins of 62 patients with schizophrenia and 53 healthy comparison subjects with Val-Val, Val-Met, and M
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。